Patents by Inventor Daniel Rosewater

Daniel Rosewater has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heteroaryl fused aminoalkyl imidazole derivatives: selective modulators of GABAreceptors
    Patent number: 7348326
    Abstract: Disclosed are compounds of the formula: or the pharmaceutically acceptable non-toxic salts thereof wherein the A, B, C, D, X, R1, R2, R3, R4, R5, and R6, are variables defined herein, which compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors, and are therefore useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, depression, overdose with benzodiazepine drugs, and enhancement of memory and alertness.
    Type: Grant
    Filed: December 6, 2005
    Date of Patent: March 25, 2008
    Assignee: Neurogen Corporation
    Inventors: Robert DeSimone, Alan Hutchison, Kenneth Shaw, Daniel Rosewater
  • Heteroaryl fused aminoalkyl imidazole derivates: selective modulators of GABAA receptors
    Publication number: 20060160842
    Abstract: Disclosed are compounds of the formula: or the pharmaceutically acceptable non-toxic salts thereof wherein the A, B, C, D, X, R1, R2, R3, R4, R5, and R6, are variables defined herein, which compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors, and are therefore useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, depression, overdose with benzodiazepine drugs, and enhancement of memory and alertness.
    Type: Application
    Filed: December 6, 2005
    Publication date: July 20, 2006
    Applicant: Neurogen Corporation
    Inventors: Robert DeSimone, Alan Hutchison, Kenneth Shaw, Daniel Rosewater
  • 1-azatricyclic-4-benzylpiperazines
    Publication number: 20020193364
    Abstract: Disclosed are 1-Azatricyclic-4-benzylpiperazine compounds which are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents. Pharmaceutical compositions, including packaged pharmaceutical compositions, are further provided. Compounds of the invention are also useful as probes for the localization of GABAA receptors in tissue samples.
    Type: Application
    Filed: May 7, 2002
    Publication date: December 19, 2002
    Applicant: Neurogen Corporation
    Inventors: Xiaoyan Zhang, Kevin Hodgetts, Stanislaw Rachwal, Daniel Rosewater, Andrew Thurkauf
  • 1-azatricyclic-4-benzylpiperazines
    Patent number: 6403591
    Abstract: Disclosed are 1-Azatricyclic-4-benzylpiperazine compounds which are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents. Pharmaceutical compositions, including packaged pharmaceutical compositions, are further provided. Compounds of the invention are also useful as probes for the localization of GABAA receptors in tissue samples.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: June 11, 2002
    Assignee: Neurogen Corporation
    Inventors: Kevin Hodgetts, Stanislaw Rachwal, Daniel Rosewater, Andrew Thurkauf, Xiaoyan Zhang
  • 1-azatricyclic-4-benzylpiperazines
    Publication number: 20020025956
    Abstract: Disclosed are 1-Azatricyclic-4-benzylpiperazine compounds which are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents. Pharmaceutical compositions, including packaged pharmaceutical compositions, are further provided. Compounds of the invention are also useful as probes for the localization of GABAA receptors in tissue samples.
    Type: Application
    Filed: June 28, 2001
    Publication date: February 28, 2002
    Inventors: Kevin Hodgetts, Stanislaw Rachwal, Daniel Rosewater, Andrew Thurkauf, Xiaoyan Zhang
  • 1-azatricyclic-4-benzylpiperazines
    Patent number: 6294530
    Abstract: Disclosed are 1-Azatricyclic-4-benzylpiperazine compounds which are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents. Pharmaceutical compositions, including packaged pharmaceutical compositions, are further provided. Compounds of the invention are also useful as probes for the localization of GABAA receptors in tissue samples.
    Type: Grant
    Filed: June 14, 2000
    Date of Patent: September 25, 2001
    Assignee: Neurogen Corporation
    Inventors: Xiaoyan Zhang, Kevin Hodgetts, Stanislaw Rachwal, Daniel Rosewater, Andrew Thurkauf